Design Therapeutics (DSGN) Enterprise Value (2020 - 2026)
Design Therapeutics (DSGN) reported Enterprise Value of -$222.8 million for Q1 2026, up 2.98% on a YoY basis from -$216.4 million in Q1 2025, and down 1.35% sequentially from -$219.8 million in Q4 2025.
Design Therapeutics (DSGN) Enterprise Value (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Enterprise Value data on file, last reported at -$222.8 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 2.98% year-over-year to -$222.8 million; the trailing twelve-month figure through Mar 2026 stood at -$222.8 million (up 2.98% YoY), and the FY2025 full-year result was -$219.8 million, up 10.44% from the prior year.
- Enterprise Value eased to -$222.8 million in Q1 2026, from -$219.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$206.0 million in Q3 2025 to a low of -$371.2 million in Q1 2022.
- A 5-year average of -$277.8 million and a median of -$270.7 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value increased 18.93% in 2025 and climbed 2.98% in 2026, its largest moves.
- Tracing DSGN's Enterprise Value over 5 years: stood at -$330.4 million in 2022, then increased by 14.71% to -$281.8 million in 2023, then increased by 12.89% to -$245.5 million in 2024, then grew by 10.44% to -$219.8 million in 2025, then retreated by 1.35% to -$222.8 million in 2026.
- Business Quant data shows DSGN's Enterprise Value at -$222.8 million in Q1 2026, -$219.8 million in Q4 2025, and -$206.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Design Therapeutics | 725.54 Mn | 502.72 Mn | - | -222.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -222.82 Mn |
| Dec 31, 2025 | -219.85 Mn |
| Sep 30, 2025 | -205.97 Mn |
| Jun 30, 2025 | -216.28 Mn |
| Mar 31, 2025 | -229.67 Mn |
| Dec 31, 2024 | -245.48 Mn |
| Sep 30, 2024 | -254.07 Mn |
| Jun 30, 2024 | -261.02 Mn |
| Mar 31, 2024 | -270.69 Mn |
| Dec 31, 2023 | -281.80 Mn |
| Sep 30, 2023 | -290.94 Mn |
| Jun 30, 2023 | -303.09 Mn |
| Mar 31, 2023 | -315.39 Mn |
| Dec 31, 2022 | -330.39 Mn |
| Sep 30, 2022 | -344.23 Mn |
| Jun 30, 2022 | -359.38 Mn |
| Mar 31, 2022 | -371.22 Mn |
| Dec 31, 2021 | -384.06 Mn |
| Sep 30, 2021 | -357.77 Mn |
| Jun 30, 2021 | -402.84 Mn |